These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19887009)

  • 1. Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.
    Lorick SA; Fishbein D; Weintraub E; Wortley PM; Lee GM; Zhou F; Davis R
    BMC Infect Dis; 2009 Nov; 9():175. PubMed ID: 19887009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.
    Enger KS; Stokley S
    J Adolesc Health; 2007 May; 40(5):398-404. PubMed ID: 17448396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adolescent vaccine co-administration and coverage in New York City: 2007-2013.
    Sull M; Eavey J; Papadouka V; Mandell R; Hansen MA; Zucker JR
    Pediatrics; 2014 Dec; 134(6):e1576-83. PubMed ID: 25384490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal conjugate vaccination among adolescents aged 13-17 years, United States, 2007.
    Lu PJ; Jain N; Cohn AC
    Vaccine; 2010 Mar; 28(11):2350-5. PubMed ID: 20044055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal Conjugate and Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccination Among HIV-infected Youth.
    Setse RW; Siberry GK; Moss WJ; Wheeling J; Bohannon BA; Dominguez KL;
    Pediatr Infect Dis J; 2016 May; 35(5):e152-7. PubMed ID: 26855409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician perspectives to inform a new recommendation for meningococcal conjugate vaccine (MCV4).
    Clark SJ; Cowan AE; Stokley S; Bilukha O; Davis MM
    J Adolesc Health; 2006 Dec; 39(6):850-5. PubMed ID: 17116515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(40):1023-5. PubMed ID: 16224452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.
    Irving SA; Groom HC; Dandamudi P; Daley MF; Donahue JG; Gee J; Hechter R; Jackson LA; Klein NP; Liles E; Myers TR; Stokley S
    Vaccine; 2022 Feb; 40(9):1246-1252. PubMed ID: 35125221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination coverage among adolescents aged 13-17 years - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(40):1100-3. PubMed ID: 18846032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
    Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
    Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACOG Committee Opinion number 314, September 2005. Meningococcal vaccination for adolescents.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2005 Sep; 106(3):667-9. PubMed ID: 16135612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations.
    Southern J; Gelb D; Andrews N; Waight PA; Morris R; Cartwright K; Miller E
    Hum Vaccin; 2006; 2(6):237-42. PubMed ID: 17102644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.
    Mehlhorn AJ; Balcer HE; Sucher BJ
    Ann Pharmacother; 2006 Apr; 40(4):666-73. PubMed ID: 16595570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of meningococcal vaccines in the United States.
    Bilukha O; Messonnier N; Fischer M
    Pediatr Infect Dis J; 2007 May; 26(5):371-6. PubMed ID: 17468644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
    Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
    Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.